دورية أكاديمية
Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
العنوان: | Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. |
---|---|
المؤلفون: | Young, Philip, Elghawy, Omar, Mock, Joseph, Wynter, Emmett, Gentzler, Ryan D., Martin, Linda W., Novicoff, Wendy, Hall, Richard |
المصدر: | Current Oncology; Jan2024, Vol. 31 Issue 1, p260-273, 14p |
مصطلحات موضوعية: | NON-small-cell lung carcinoma, IMMUNE checkpoint inhibitors, TREATMENT duration, OVERALL survival, IPILIMUMAB, BUPRENORPHINE, OPIOIDS |
الشركة/الكيان: | UNIVERSITY of Virginia |
مستخلص: | Immune checkpoint inhibitors (ICI) have significantly improved outcomes in advanced non-small cell lung cancer (NSCLC). We evaluated the effect of opioid use on outcomes in patients receiving ICI either alone or with chemotherapy. We conducted a retrospective review of 209 patients with advanced NSCLC who received an ICI at the University of Virginia between 1 February 2015 and 1 January 2020. We performed univariate and multivariate analyses to evaluate the impact of opioid use on duration of therapy (DOT) and overall survival (OS). Patients with no or low opioid use (n = 172) had a median DOT of 12.2 months (95% CI: 6.9–17.4) compared to 1.9 months (95% CI: 1.8–2.0) for those with high opioid use (n = 37, HR 0.26 95% CI: 0.17–0.40, p < 0.001). Patients with no or low opioid use had a median OS of 22.6 months (95% CI: 14.8–30.4) compared to 3.8 months (95% CI: 2.7–4.9) for those with high opioid use (HR 0.26 95% CI: 0.17–0.40 p < 0.001). High opioid use was associated with a shorter DOT and worse OS. This difference remained significant when accounting for possible confounding variables. These data warrant investigation of possible mechanistic interactions between opioids, tumor progression, and ICIs, as well as prospective evaluation of opioid-sparing pain management strategies, where possible. [ABSTRACT FROM AUTHOR] |
Copyright of Current Oncology is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
قاعدة البيانات: | Complementary Index |
ResultId |
1 |
---|---|
Header |
edb Complementary Index 175035265 1040 6 Academic Journal academicJournal 1040.49658203125 |
PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=175035265&custid=s6537998&authtype=sso |
FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edb&genre=article&issn=11980052&ISBN=&volume=31&issue=1&date=20240101&spage=260&pages=260-273&title=Current Oncology&atitle=Impact%20of%20Opioid%20Use%20on%20Duration%20of%20Therapy%20and%20Overall%20Survival%20for%20Patients%20with%20Advanced%20Non-Small%20Cell%20Lung%20Cancer%20Treated%20with%20Immune%20Checkpoint%20Inhibitors.&id=DOI:10.3390/curroncol31010017 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Young%2C+Philip%22">Young, Philip</searchLink><br /><searchLink fieldCode="AR" term="%22Elghawy%2C+Omar%22">Elghawy, Omar</searchLink><br /><searchLink fieldCode="AR" term="%22Mock%2C+Joseph%22">Mock, Joseph</searchLink><br /><searchLink fieldCode="AR" term="%22Wynter%2C+Emmett%22">Wynter, Emmett</searchLink><br /><searchLink fieldCode="AR" term="%22Gentzler%2C+Ryan+D%2E%22">Gentzler, Ryan D.</searchLink><br /><searchLink fieldCode="AR" term="%22Martin%2C+Linda+W%2E%22">Martin, Linda W.</searchLink><br /><searchLink fieldCode="AR" term="%22Novicoff%2C+Wendy%22">Novicoff, Wendy</searchLink><br /><searchLink fieldCode="AR" term="%22Hall%2C+Richard%22">Hall, Richard</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Current Oncology; Jan2024, Vol. 31 Issue 1, p260-273, 14p ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22NON-small-cell+lung+carcinoma%22">NON-small-cell lung carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22IMMUNE+checkpoint+inhibitors%22">IMMUNE checkpoint inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22TREATMENT+duration%22">TREATMENT duration</searchLink><br /><searchLink fieldCode="DE" term="%22OVERALL+survival%22">OVERALL survival</searchLink><br /><searchLink fieldCode="DE" term="%22IPILIMUMAB%22">IPILIMUMAB</searchLink><br /><searchLink fieldCode="DE" term="%22BUPRENORPHINE%22">BUPRENORPHINE</searchLink><br /><searchLink fieldCode="DE" term="%22OPIOIDS%22">OPIOIDS</searchLink> ) Array ( [Name] => SubjectCompany [Label] => Company/Entity [Group] => Su [Data] => <searchLink fieldCode="CO" term="%22UNIVERSITY+of+Virginia%22">UNIVERSITY of Virginia</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Immune checkpoint inhibitors (ICI) have significantly improved outcomes in advanced non-small cell lung cancer (NSCLC). We evaluated the effect of opioid use on outcomes in patients receiving ICI either alone or with chemotherapy. We conducted a retrospective review of 209 patients with advanced NSCLC who received an ICI at the University of Virginia between 1 February 2015 and 1 January 2020. We performed univariate and multivariate analyses to evaluate the impact of opioid use on duration of therapy (DOT) and overall survival (OS). Patients with no or low opioid use (n = 172) had a median DOT of 12.2 months (95% CI: 6.9–17.4) compared to 1.9 months (95% CI: 1.8–2.0) for those with high opioid use (n = 37, HR 0.26 95% CI: 0.17–0.40, p < 0.001). Patients with no or low opioid use had a median OS of 22.6 months (95% CI: 14.8–30.4) compared to 3.8 months (95% CI: 2.7–4.9) for those with high opioid use (HR 0.26 95% CI: 0.17–0.40 p < 0.001). High opioid use was associated with a shorter DOT and worse OS. This difference remained significant when accounting for possible confounding variables. These data warrant investigation of possible mechanistic interactions between opioids, tumor progression, and ICIs, as well as prospective evaluation of opioid-sparing pain management strategies, where possible. [ABSTRACT FROM AUTHOR] ) Array ( [Name] => Abstract [Label] => [Group] => Ab [Data] => <i>Copyright of Current Oncology is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) ) |
RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3390/curroncol31010017
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 14
[StartPage] => 260
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => UNIVERSITY of Virginia
[Type] => general
)
[1] => Array
(
[SubjectFull] => NON-small-cell lung carcinoma
[Type] => general
)
[2] => Array
(
[SubjectFull] => IMMUNE checkpoint inhibitors
[Type] => general
)
[3] => Array
(
[SubjectFull] => TREATMENT duration
[Type] => general
)
[4] => Array
(
[SubjectFull] => OVERALL survival
[Type] => general
)
[5] => Array
(
[SubjectFull] => IPILIMUMAB
[Type] => general
)
[6] => Array
(
[SubjectFull] => BUPRENORPHINE
[Type] => general
)
[7] => Array
(
[SubjectFull] => OPIOIDS
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Young, Philip
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Elghawy, Omar
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mock, Joseph
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wynter, Emmett
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gentzler, Ryan D.
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Martin, Linda W.
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Novicoff, Wendy
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hall, Richard
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Text] => Jan2024
[Type] => published
[Y] => 2024
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 11980052
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 31
)
[1] => Array
(
[Type] => issue
[Value] => 1
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Current Oncology
[Type] => main
)
)
)
)
)
)
)
|
IllustrationInfo |